Monograph: |
BULAQUINE
It is a mixture of 3{-1-[4-6(-methoxy-8-quinolinyl)
amino]pentyl}amino}ethylidenedihydro-2-(3H)furanone and it's tautomers.
Indications : Treatment and prevention of relapse
of P.vivax malaria.
Dosage : The exact dosage recommended for
clinical use is 25mg once daily for 5 days. This should
be given along with chloroquine for complete cure of
malaria. It should be started from Day 2 of chloroquine
therapy
Contra-indications: Rheumatoid arthritis, systemic
lupus erythematosus, concurrent administration of
drugs known to cause haemolysis.
Special Precautions : There is no need to conduct
a G-6PDH deficiency test before administering
bulaquine. However in patients with confirmed Q-
6PDH deficiency caution is necessary. It use in
pregnant and lactating women should be avoided, as
controlled trials to confirm it safety and tolerability
in these conditions have yet to be undertaken. No
studies have been done in children.
Side effects : Clinical data generated so far has not
shown any adverse drug reactions.
Drug Interactions: Specific studies with other drugs
have bot been undertaken except with chloroquine
where it was concurrently used in the phase 11/111
clinical trials without any adverse effects.
|